ca 074 methyl ester Search Results


cathepsin b inhibitor  (MedChemExpress)
94
MedChemExpress cathepsin b inhibitor
( A ) Representative immunostaining of cathepsin B/GAL3/CD68 in WT/WT and WT/GAL3 –/– chimera mice 3 d after tMCAO. Scale bar: 50 μm. ( B ) Quantification of <t>cathepsin</t> <t>B</t> + staining areas within CD68 + areas of macrophages. ( C ) Quantification of CD68 + areas. N = 7/group. ( D ) MAP2 staining of brain in vehicle- or CA-074–treated (10 mg/kg, i.v., 2 h after tMCAO and then daily for 2 d) WT/WT or WT/GAL3 –/– chimeric mice 3 d after tMCAO. ( E ) Quantification of brain infarct volume. N = 5–6/group. ( F ) Cathepsin B activity was analyzed using the Magic Red cathepsin kit in GAL3-KO or WT BMDMs with vehicle or TD139 (10 μM) treatment. Scale bar: 50 μm. ( G ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. ( H ) Representative Magic Red staining in WT and GAL3-KO BMDMs treated with or without WT or GAL3-KO lysate for 6 h. Scale bars: 50 μm. ( I ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. Gray blocks show SD. *** P < 0.001 versus (WT BMDM + WT lysate); # P < 0.05, ## P < 0.01 versus (KO BMDM + WT lysate); $ P < 0.05 versus (WT BMDM + KO lysate). ( J ) Immunoblot and quantification of cathepsin B expression in cytosol of BMDMs under the indicated conditions for 6 h. N = 3/condition. ( K ) Coimmunostaining of LAMP2 and cathepsin B in BMDMs under specified conditions for 6 h. Scale bars: 5 μm, 2 μm (zoom). ( L ) Fluorescence intensity profiles of cathepsin B and LAMP2. ( M ) Pearson’s correlation analyses of LAMP2 and cathepsin B. N = 7/condition. ( N ) BMDMs in inserts treated with brain lysates and CA-074 (10 μM) or vehicle were cocultured with OGD neurons. Coverage areas of MAP2-stained neurons were quantified. N = 6/condition. Scale bar: 40 μm. * P < 0.05, ** P < 0.01, *** P < 0.001. Two-tailed, unpaired Student’s t test ( B , C , and E ) or 1-way ( G , J , M , and N ) or 2-way ( I ) ANOVA and Bonferroni’s test.
Cathepsin B Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cathepsin b inhibitor/product/MedChemExpress
Average 94 stars, based on 1 article reviews
cathepsin b inhibitor - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
ca 074 methyl ester  (TargetMol)
94
TargetMol ca 074 methyl ester
( A ) Representative immunostaining of cathepsin B/GAL3/CD68 in WT/WT and WT/GAL3 –/– chimera mice 3 d after tMCAO. Scale bar: 50 μm. ( B ) Quantification of cathepsin B + staining areas within CD68 + areas of macrophages. ( C ) Quantification of CD68 + areas. N = 7/group. ( D ) MAP2 staining of brain in vehicle- or <t>CA-074–treated</t> (10 mg/kg, i.v., 2 h after tMCAO and then daily for 2 d) WT/WT or WT/GAL3 –/– chimeric mice 3 d after tMCAO. ( E ) Quantification of brain infarct volume. N = 5–6/group. ( F ) Cathepsin B activity was analyzed using the Magic Red cathepsin kit in GAL3-KO or WT BMDMs with vehicle or TD139 (10 μM) treatment. Scale bar: 50 μm. ( G ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. ( H ) Representative Magic Red staining in WT and GAL3-KO BMDMs treated with or without WT or GAL3-KO lysate for 6 h. Scale bars: 50 μm. ( I ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. Gray blocks show SD. *** P < 0.001 versus (WT BMDM + WT lysate); # P < 0.05, ## P < 0.01 versus (KO BMDM + WT lysate); $ P < 0.05 versus (WT BMDM + KO lysate). ( J ) Immunoblot and quantification of cathepsin B expression in cytosol of BMDMs under the indicated conditions for 6 h. N = 3/condition. ( K ) Coimmunostaining of LAMP2 and cathepsin B in BMDMs under specified conditions for 6 h. Scale bars: 5 μm, 2 μm (zoom). ( L ) Fluorescence intensity profiles of cathepsin B and LAMP2. ( M ) Pearson’s correlation analyses of LAMP2 and cathepsin B. N = 7/condition. ( N ) BMDMs in inserts treated with brain lysates and CA-074 (10 μM) or vehicle were cocultured with OGD neurons. Coverage areas of MAP2-stained neurons were quantified. N = 6/condition. Scale bar: 40 μm. * P < 0.05, ** P < 0.01, *** P < 0.001. Two-tailed, unpaired Student’s t test ( B , C , and E ) or 1-way ( G , J , M , and N ) or 2-way ( I ) ANOVA and Bonferroni’s test.
Ca 074 Methyl Ester, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ca 074 methyl ester/product/TargetMol
Average 94 stars, based on 1 article reviews
ca 074 methyl ester - by Bioz Stars, 2026-05
94/100 stars
  Buy from Supplier
s7420  (Selleck Chemicals)
93
Selleck Chemicals s7420
( A ) Representative immunostaining of cathepsin B/GAL3/CD68 in WT/WT and WT/GAL3 –/– chimera mice 3 d after tMCAO. Scale bar: 50 μm. ( B ) Quantification of cathepsin B + staining areas within CD68 + areas of macrophages. ( C ) Quantification of CD68 + areas. N = 7/group. ( D ) MAP2 staining of brain in vehicle- or <t>CA-074–treated</t> (10 mg/kg, i.v., 2 h after tMCAO and then daily for 2 d) WT/WT or WT/GAL3 –/– chimeric mice 3 d after tMCAO. ( E ) Quantification of brain infarct volume. N = 5–6/group. ( F ) Cathepsin B activity was analyzed using the Magic Red cathepsin kit in GAL3-KO or WT BMDMs with vehicle or TD139 (10 μM) treatment. Scale bar: 50 μm. ( G ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. ( H ) Representative Magic Red staining in WT and GAL3-KO BMDMs treated with or without WT or GAL3-KO lysate for 6 h. Scale bars: 50 μm. ( I ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. Gray blocks show SD. *** P < 0.001 versus (WT BMDM + WT lysate); # P < 0.05, ## P < 0.01 versus (KO BMDM + WT lysate); $ P < 0.05 versus (WT BMDM + KO lysate). ( J ) Immunoblot and quantification of cathepsin B expression in cytosol of BMDMs under the indicated conditions for 6 h. N = 3/condition. ( K ) Coimmunostaining of LAMP2 and cathepsin B in BMDMs under specified conditions for 6 h. Scale bars: 5 μm, 2 μm (zoom). ( L ) Fluorescence intensity profiles of cathepsin B and LAMP2. ( M ) Pearson’s correlation analyses of LAMP2 and cathepsin B. N = 7/condition. ( N ) BMDMs in inserts treated with brain lysates and CA-074 (10 μM) or vehicle were cocultured with OGD neurons. Coverage areas of MAP2-stained neurons were quantified. N = 6/condition. Scale bar: 40 μm. * P < 0.05, ** P < 0.01, *** P < 0.001. Two-tailed, unpaired Student’s t test ( B , C , and E ) or 1-way ( G , J , M , and N ) or 2-way ( I ) ANOVA and Bonferroni’s test.
S7420, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/s7420/product/Selleck Chemicals
Average 93 stars, based on 1 article reviews
s7420 - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
ca 074 me  (Santa Cruz Biotechnology)
91
Santa Cruz Biotechnology ca 074 me
( A ) Representative immunostaining of cathepsin B/GAL3/CD68 in WT/WT and WT/GAL3 –/– chimera mice 3 d after tMCAO. Scale bar: 50 μm. ( B ) Quantification of cathepsin B + staining areas within CD68 + areas of macrophages. ( C ) Quantification of CD68 + areas. N = 7/group. ( D ) MAP2 staining of brain in vehicle- or <t>CA-074–treated</t> (10 mg/kg, i.v., 2 h after tMCAO and then daily for 2 d) WT/WT or WT/GAL3 –/– chimeric mice 3 d after tMCAO. ( E ) Quantification of brain infarct volume. N = 5–6/group. ( F ) Cathepsin B activity was analyzed using the Magic Red cathepsin kit in GAL3-KO or WT BMDMs with vehicle or TD139 (10 μM) treatment. Scale bar: 50 μm. ( G ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. ( H ) Representative Magic Red staining in WT and GAL3-KO BMDMs treated with or without WT or GAL3-KO lysate for 6 h. Scale bars: 50 μm. ( I ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. Gray blocks show SD. *** P < 0.001 versus (WT BMDM + WT lysate); # P < 0.05, ## P < 0.01 versus (KO BMDM + WT lysate); $ P < 0.05 versus (WT BMDM + KO lysate). ( J ) Immunoblot and quantification of cathepsin B expression in cytosol of BMDMs under the indicated conditions for 6 h. N = 3/condition. ( K ) Coimmunostaining of LAMP2 and cathepsin B in BMDMs under specified conditions for 6 h. Scale bars: 5 μm, 2 μm (zoom). ( L ) Fluorescence intensity profiles of cathepsin B and LAMP2. ( M ) Pearson’s correlation analyses of LAMP2 and cathepsin B. N = 7/condition. ( N ) BMDMs in inserts treated with brain lysates and CA-074 (10 μM) or vehicle were cocultured with OGD neurons. Coverage areas of MAP2-stained neurons were quantified. N = 6/condition. Scale bar: 40 μm. * P < 0.05, ** P < 0.01, *** P < 0.001. Two-tailed, unpaired Student’s t test ( B , C , and E ) or 1-way ( G , J , M , and N ) or 2-way ( I ) ANOVA and Bonferroni’s test.
Ca 074 Me, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ca 074 me/product/Santa Cruz Biotechnology
Average 91 stars, based on 1 article reviews
ca 074 me - by Bioz Stars, 2026-05
91/100 stars
  Buy from Supplier
ca 074me  (Chem Impex International)
95
Chem Impex International ca 074me
( A ) Representative immunostaining of cathepsin B/GAL3/CD68 in WT/WT and WT/GAL3 –/– chimera mice 3 d after tMCAO. Scale bar: 50 μm. ( B ) Quantification of cathepsin B + staining areas within CD68 + areas of macrophages. ( C ) Quantification of CD68 + areas. N = 7/group. ( D ) MAP2 staining of brain in vehicle- or <t>CA-074–treated</t> (10 mg/kg, i.v., 2 h after tMCAO and then daily for 2 d) WT/WT or WT/GAL3 –/– chimeric mice 3 d after tMCAO. ( E ) Quantification of brain infarct volume. N = 5–6/group. ( F ) Cathepsin B activity was analyzed using the Magic Red cathepsin kit in GAL3-KO or WT BMDMs with vehicle or TD139 (10 μM) treatment. Scale bar: 50 μm. ( G ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. ( H ) Representative Magic Red staining in WT and GAL3-KO BMDMs treated with or without WT or GAL3-KO lysate for 6 h. Scale bars: 50 μm. ( I ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. Gray blocks show SD. *** P < 0.001 versus (WT BMDM + WT lysate); # P < 0.05, ## P < 0.01 versus (KO BMDM + WT lysate); $ P < 0.05 versus (WT BMDM + KO lysate). ( J ) Immunoblot and quantification of cathepsin B expression in cytosol of BMDMs under the indicated conditions for 6 h. N = 3/condition. ( K ) Coimmunostaining of LAMP2 and cathepsin B in BMDMs under specified conditions for 6 h. Scale bars: 5 μm, 2 μm (zoom). ( L ) Fluorescence intensity profiles of cathepsin B and LAMP2. ( M ) Pearson’s correlation analyses of LAMP2 and cathepsin B. N = 7/condition. ( N ) BMDMs in inserts treated with brain lysates and CA-074 (10 μM) or vehicle were cocultured with OGD neurons. Coverage areas of MAP2-stained neurons were quantified. N = 6/condition. Scale bar: 40 μm. * P < 0.05, ** P < 0.01, *** P < 0.001. Two-tailed, unpaired Student’s t test ( B , C , and E ) or 1-way ( G , J , M , and N ) or 2-way ( I ) ANOVA and Bonferroni’s test.
Ca 074me, supplied by Chem Impex International, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ca 074me/product/Chem Impex International
Average 95 stars, based on 1 article reviews
ca 074me - by Bioz Stars, 2026-05
95/100 stars
  Buy from Supplier
ca-074 methyl ester  (Toronto Research Chemicals)
N/A
   Buy from Supplier
ca-074 methyl ester (ca-074 me)  (Aladdin Scientific Corporation)
N/A
InformationCA-074 methyl ester (CA-074 Me) CA-074 methyl ester (CA-074 Me, Cathepsin B Inhibitor IV) is a membrane-permeable derivative of CA-074 and acts as an irreversible cathepsin B inhibitor.In vitroCA-074Me is able to inhibit cathepsin L
   Buy from Supplier
ca 074 methyl ester  (Cayman Chemical)
N/A
CA 074 methyl ester is a cell permeable inhibitor of cathepsin B and L in vivo and in whole cells The methyl ester is hydrolyzed by intracellular esterases releasing the active inhibitor CA 074 This
   Buy from Supplier
ca-074 methyl ester  (Aladdin Scientific Corporation)
N/A
CA-074 methyl ester is a cell-permeable analog of CA-074 that acts as an irreversible cathepsin B inhibitor. CA-074 methyl ester is reported to inhibit bone reabsorption in rodent models and shown to inhibit B16 melanoma
   Buy from Supplier
ca-074 methyl ester  (BOC Sciences)
N/A
CA-074 Me is a membrane-permeable inhibitor of irreversible cathepsin B derived from CA-074. CA-074 Me would be hydrolyzed by intracellular esterases to CA-074, the active compound.
   Buy from Supplier

Image Search Results


( A ) Representative immunostaining of cathepsin B/GAL3/CD68 in WT/WT and WT/GAL3 –/– chimera mice 3 d after tMCAO. Scale bar: 50 μm. ( B ) Quantification of cathepsin B + staining areas within CD68 + areas of macrophages. ( C ) Quantification of CD68 + areas. N = 7/group. ( D ) MAP2 staining of brain in vehicle- or CA-074–treated (10 mg/kg, i.v., 2 h after tMCAO and then daily for 2 d) WT/WT or WT/GAL3 –/– chimeric mice 3 d after tMCAO. ( E ) Quantification of brain infarct volume. N = 5–6/group. ( F ) Cathepsin B activity was analyzed using the Magic Red cathepsin kit in GAL3-KO or WT BMDMs with vehicle or TD139 (10 μM) treatment. Scale bar: 50 μm. ( G ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. ( H ) Representative Magic Red staining in WT and GAL3-KO BMDMs treated with or without WT or GAL3-KO lysate for 6 h. Scale bars: 50 μm. ( I ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. Gray blocks show SD. *** P < 0.001 versus (WT BMDM + WT lysate); # P < 0.05, ## P < 0.01 versus (KO BMDM + WT lysate); $ P < 0.05 versus (WT BMDM + KO lysate). ( J ) Immunoblot and quantification of cathepsin B expression in cytosol of BMDMs under the indicated conditions for 6 h. N = 3/condition. ( K ) Coimmunostaining of LAMP2 and cathepsin B in BMDMs under specified conditions for 6 h. Scale bars: 5 μm, 2 μm (zoom). ( L ) Fluorescence intensity profiles of cathepsin B and LAMP2. ( M ) Pearson’s correlation analyses of LAMP2 and cathepsin B. N = 7/condition. ( N ) BMDMs in inserts treated with brain lysates and CA-074 (10 μM) or vehicle were cocultured with OGD neurons. Coverage areas of MAP2-stained neurons were quantified. N = 6/condition. Scale bar: 40 μm. * P < 0.05, ** P < 0.01, *** P < 0.001. Two-tailed, unpaired Student’s t test ( B , C , and E ) or 1-way ( G , J , M , and N ) or 2-way ( I ) ANOVA and Bonferroni’s test.

Journal: The Journal of Clinical Investigation

Article Title: Galectin-3 mediates lysosome-related inflammation within monocyte-derived macrophages in a mouse model of ischemic brain injury

doi: 10.1172/JCI194139

Figure Lengend Snippet: ( A ) Representative immunostaining of cathepsin B/GAL3/CD68 in WT/WT and WT/GAL3 –/– chimera mice 3 d after tMCAO. Scale bar: 50 μm. ( B ) Quantification of cathepsin B + staining areas within CD68 + areas of macrophages. ( C ) Quantification of CD68 + areas. N = 7/group. ( D ) MAP2 staining of brain in vehicle- or CA-074–treated (10 mg/kg, i.v., 2 h after tMCAO and then daily for 2 d) WT/WT or WT/GAL3 –/– chimeric mice 3 d after tMCAO. ( E ) Quantification of brain infarct volume. N = 5–6/group. ( F ) Cathepsin B activity was analyzed using the Magic Red cathepsin kit in GAL3-KO or WT BMDMs with vehicle or TD139 (10 μM) treatment. Scale bar: 50 μm. ( G ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. ( H ) Representative Magic Red staining in WT and GAL3-KO BMDMs treated with or without WT or GAL3-KO lysate for 6 h. Scale bars: 50 μm. ( I ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. Gray blocks show SD. *** P < 0.001 versus (WT BMDM + WT lysate); # P < 0.05, ## P < 0.01 versus (KO BMDM + WT lysate); $ P < 0.05 versus (WT BMDM + KO lysate). ( J ) Immunoblot and quantification of cathepsin B expression in cytosol of BMDMs under the indicated conditions for 6 h. N = 3/condition. ( K ) Coimmunostaining of LAMP2 and cathepsin B in BMDMs under specified conditions for 6 h. Scale bars: 5 μm, 2 μm (zoom). ( L ) Fluorescence intensity profiles of cathepsin B and LAMP2. ( M ) Pearson’s correlation analyses of LAMP2 and cathepsin B. N = 7/condition. ( N ) BMDMs in inserts treated with brain lysates and CA-074 (10 μM) or vehicle were cocultured with OGD neurons. Coverage areas of MAP2-stained neurons were quantified. N = 6/condition. Scale bar: 40 μm. * P < 0.05, ** P < 0.01, *** P < 0.001. Two-tailed, unpaired Student’s t test ( B , C , and E ) or 1-way ( G , J , M , and N ) or 2-way ( I ) ANOVA and Bonferroni’s test.

Article Snippet: Stock solutions of TD139, a specific GAL3 inhibitor (TargetMol) and CA-074 methyl ester, a specific cathepsin B inhibitor (MedChem Express) were prepared at concentrations of 10 mM for in vitro use and 10 mg/mL for in vivo use.

Techniques: Immunostaining, Staining, Activity Assay, Western Blot, Expressing, Fluorescence, Two Tailed Test

( A ) Representative immunostaining of cathepsin B/GAL3/CD68 in WT/WT and WT/GAL3 –/– chimera mice 3 d after tMCAO. Scale bar: 50 μm. ( B ) Quantification of cathepsin B + staining areas within CD68 + areas of macrophages. ( C ) Quantification of CD68 + areas. N = 7/group. ( D ) MAP2 staining of brain in vehicle- or CA-074–treated (10 mg/kg, i.v., 2 h after tMCAO and then daily for 2 d) WT/WT or WT/GAL3 –/– chimeric mice 3 d after tMCAO. ( E ) Quantification of brain infarct volume. N = 5–6/group. ( F ) Cathepsin B activity was analyzed using the Magic Red cathepsin kit in GAL3-KO or WT BMDMs with vehicle or TD139 (10 μM) treatment. Scale bar: 50 μm. ( G ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. ( H ) Representative Magic Red staining in WT and GAL3-KO BMDMs treated with or without WT or GAL3-KO lysate for 6 h. Scale bars: 50 μm. ( I ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. Gray blocks show SD. *** P < 0.001 versus (WT BMDM + WT lysate); # P < 0.05, ## P < 0.01 versus (KO BMDM + WT lysate); $ P < 0.05 versus (WT BMDM + KO lysate). ( J ) Immunoblot and quantification of cathepsin B expression in cytosol of BMDMs under the indicated conditions for 6 h. N = 3/condition. ( K ) Coimmunostaining of LAMP2 and cathepsin B in BMDMs under specified conditions for 6 h. Scale bars: 5 μm, 2 μm (zoom). ( L ) Fluorescence intensity profiles of cathepsin B and LAMP2. ( M ) Pearson’s correlation analyses of LAMP2 and cathepsin B. N = 7/condition. ( N ) BMDMs in inserts treated with brain lysates and CA-074 (10 μM) or vehicle were cocultured with OGD neurons. Coverage areas of MAP2-stained neurons were quantified. N = 6/condition. Scale bar: 40 μm. * P < 0.05, ** P < 0.01, *** P < 0.001. Two-tailed, unpaired Student’s t test ( B , C , and E ) or 1-way ( G , J , M , and N ) or 2-way ( I ) ANOVA and Bonferroni’s test.

Journal: The Journal of Clinical Investigation

Article Title: Galectin-3 mediates lysosome-related inflammation within monocyte-derived macrophages in a mouse model of ischemic brain injury

doi: 10.1172/JCI194139

Figure Lengend Snippet: ( A ) Representative immunostaining of cathepsin B/GAL3/CD68 in WT/WT and WT/GAL3 –/– chimera mice 3 d after tMCAO. Scale bar: 50 μm. ( B ) Quantification of cathepsin B + staining areas within CD68 + areas of macrophages. ( C ) Quantification of CD68 + areas. N = 7/group. ( D ) MAP2 staining of brain in vehicle- or CA-074–treated (10 mg/kg, i.v., 2 h after tMCAO and then daily for 2 d) WT/WT or WT/GAL3 –/– chimeric mice 3 d after tMCAO. ( E ) Quantification of brain infarct volume. N = 5–6/group. ( F ) Cathepsin B activity was analyzed using the Magic Red cathepsin kit in GAL3-KO or WT BMDMs with vehicle or TD139 (10 μM) treatment. Scale bar: 50 μm. ( G ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. ( H ) Representative Magic Red staining in WT and GAL3-KO BMDMs treated with or without WT or GAL3-KO lysate for 6 h. Scale bars: 50 μm. ( I ) Quantification of the percentages of Magic Red + cells among total cells. N = 6/condition. Gray blocks show SD. *** P < 0.001 versus (WT BMDM + WT lysate); # P < 0.05, ## P < 0.01 versus (KO BMDM + WT lysate); $ P < 0.05 versus (WT BMDM + KO lysate). ( J ) Immunoblot and quantification of cathepsin B expression in cytosol of BMDMs under the indicated conditions for 6 h. N = 3/condition. ( K ) Coimmunostaining of LAMP2 and cathepsin B in BMDMs under specified conditions for 6 h. Scale bars: 5 μm, 2 μm (zoom). ( L ) Fluorescence intensity profiles of cathepsin B and LAMP2. ( M ) Pearson’s correlation analyses of LAMP2 and cathepsin B. N = 7/condition. ( N ) BMDMs in inserts treated with brain lysates and CA-074 (10 μM) or vehicle were cocultured with OGD neurons. Coverage areas of MAP2-stained neurons were quantified. N = 6/condition. Scale bar: 40 μm. * P < 0.05, ** P < 0.01, *** P < 0.001. Two-tailed, unpaired Student’s t test ( B , C , and E ) or 1-way ( G , J , M , and N ) or 2-way ( I ) ANOVA and Bonferroni’s test.

Article Snippet: Stock solutions of TD139, a specific GAL3 inhibitor (TargetMol) and CA-074 methyl ester, a specific cathepsin B inhibitor (MedChem Express) were prepared at concentrations of 10 mM for in vitro use and 10 mg/mL for in vivo use.

Techniques: Immunostaining, Staining, Activity Assay, Western Blot, Expressing, Fluorescence, Two Tailed Test